Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary
fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have …

Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with
inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was …

Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of complex
cause. Gastro-oesophageal reflux (GER) and microaspiration have been proposed as risk …

Rationale: Evidence suggests that tumor necrosis factor (TNF)-α plays an important role in
the pathophysiology of sarcoidosis. Objectives: To assess the efficacy of infliximab in …

Pirfenidone is an antifibrotic agent that has been evaluated in three multinational phase 3
trials in patients with idiopathic pulmonary fibrosis (IPF). We analysed pooled data from the …

Background Idiopathic pulmonary fibrosis is a fatal disease for which no effective treatment
exists. We assessed whether treatment with interferon gamma-1b improved survival …

Pulmonary arterial hypertension (PAH) is a complex disease with a poor prognosis. In recent
years, great advances have occurred in our understanding of the pathophysiologic …

Rationale: The 6-minute-walk test (6MWT) is a practical and clinically meaningful measure
of exercise tolerance with favorable performance characteristics in various cardiac and …

Rationale: Forced vital capacity (FVC) is an established measure of pulmonary function in
idiopathic pulmonary fibrosis (IPF). Evidence regarding its measurement properties and …

Rationale: Several predictors of mortality in patients with idiopathic pulmonary fibrosis have
been described; however, there is a need for a practical and accurate method of quantifying …